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INTRODUCTION
HIV infection has become a chronic disease. The devel-
opment of new therapies and the ever better quality of 
care have allowed a significant reduction in morbidity 
and mortality associated with the infection (Lohse et al., 
2007). The consequence of such success is the substantial 
increase in persons living with HIV (PLWHIV) who are 
now part of the working population and live normal lives. 
However, the presence of the virus not only often acceler-
ates and makes other diseases more serious, but also ex-
Corresponding author:
Marco Borderi
E-mail: marco.borderi@aosp.bo.it
©2018 by EDIMES - Edizioni Internazionali Srl. All rights reserved
poses PLWHIV to a greater risk of comorbidities than age 
comparable HIV-negative subjects (Guaraldi et al., 2011). 
As a consequence, therapeutic strategies for a chronic dis-
ease should take this new scenario into account. Indeed, 
pharmacological research should try to provide new drugs 
able to control or hopefully to eliminate the infection, but 
also more tolerable in the long term. Moreover, to reduce 
toxicities, the use and combination of drugs already avail-
able could differ from the past. The objective of old and 
new treatment strategies for PLWHIV should be a better 
quality of life. Indeed, a patient treated properly and as 
early as possible represents a resource not only for himself, 
but also for the community. In order to achieve this, the 
management of comorbidities should be as timely and as 
early as possible. The only way to obtain this is to facilitate 
and broaden the awareness of infectious disease special-
ists regarding a comprehensive approach to comorbidity 
management in PLWHIV. To this end, we propose a dis-
cussion among experts on the best strategies to prevent 
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SUMMARY
We propose a multidimensional first-level diagnostic assessment easy to use in routine clinical practice 
to allow infectious disease specialists to have a general and complete overview of persons living with 
HIV. Following the Delphi method, articles published from January 1, 2011 on controlled trials, clinical 
reports and observational studies dealing specifically with HIV and its co-morbidities were selected for 
review by the authors. Participants in the poll were selected among clinicians and infectious diseases 
specialists, working in 38 different dedicated HIV centres in Italy. The participants were given access to a 
website dedicated to the project and received a standardized information package containing a synopsis 
of the study and a description of the Delphi process and the selected literature. A total of 131 Items were 
divided into 10 first-level survey areas: anamnesis, objective examination, infectious diseases, osteoporosis 
diagnosis, metabolic pathologies diagnosis, cardiovascular diagnosis, nephrologic diagnosis, hepatological 
diagnosis, central nervous system diagnosis, evaluation of quality of life (QoL). This simple and concise 
first level tool identifies a few areas of multi-organ diagnostic assessment beyond the infectivity area. The 
identification of these areas will allow us to find shared and validated evaluation procedures with the 
intent to increase the likelihood of early recognition of patients at risk of comorbidity development, in 
order to facilitate more effective prevention, thereby reducing the overall impact on the quality of life of 
patients affected by this chronic illness.
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and manage comorbidities and organ damage (liver, SNC, 
heart, bone and kidney). The aim of the project was to of-
fer infectious disease specialists an appropriate algorithm 
for monitoring the health of these patients beyond the con-
trol of HIV viral load. The chosen tool, to support the dis-
cussion was a Delphi survey among Italian HIV specialists.
Objective
To propose a multidimensional first-level diagnostic as-
sessment easy to use in routine clinical practice to allow 
infectious disease specialists to have a general and com-
plete overview of PLWHIV.
MATERIALS AND METHODS
Study design
The Delphi method, originated in the 1960s, takes its 
name from the Delphic oracle’s skills of interpretation and 
foresight (Njuangang et al., 2017). It was developed at the 
RAND Corporation to obtain the most reliable consensus 
of opinion of a group of experts on a subject in a system-
atic manner (Matheson, 1982). It attempts to do this by a 
series of well-defined questionnaires based on surveys and 
feedback. This consensus statement was developed using 
the RAND/UCLA Appropriateness Method process (Bour-
rée et al., 2008). This method is a formal group judgment 
process which systematically and quantitatively combines 
expert opinion and scientific (systematic literature review) 
evidence by asking panellists to rate, discuss, and then re-
rate indicators. There is no intercommunication among 
the experts. It is the only systematic method of combining 
expert opinion and evidence. We performed a Delphi poll 
and subsequently submitted the obtained results to a re-
stricted panel of 38 experts.
Delphi questionnaire preparation
Articles published from January 1, 2011 on controlled tri-
als, clinical reports and observational studies dealing spe-
cifically with HIV and its co-morbidities were selected for 
review by the authors. All were identified by a MEDLINE 
systematic search up to and including August 2015, using 
the MESH keywords “HIV”, “comorbidity”, “risk factors in 
HIV” and “complication” (Table 1). 
At this stage, the material obtained was used to set up the 
Delphi questionnaire. The identified diagnostic proce-
dures (items of the questionnaire) were divided according 
to the area of competence (e.g. cardiology etc.) and for 
each item the following question was set up: “According 
to you, how relevant is this procedure for a first-degree as-
sessment (respectively second-degree assessment) of comor-
bidities in HIV patients?” (Table 2).
Selection of expert panel size and composition
Participants in the poll were selected among clinicians 
and infectious diseases specialists working in 38 different 
dedicated HIV centres in Italy. 38 specialists finally agreed 
to take part in the poll. The participants were given ac-
cess to a website dedicated to the project and received a 
standardized information package containing a synopsis 
of the study and a description of the Delphi process and 
the selected literature.
The survey
Between May 2016 and January 2017, the definitive list of 
diagnostic procedures in the questionnaire was submitted 
to 38 infectious diseases specialists throughout Italy. The 
steering committee planned to perform at least two Delphi 
rounds. The consensus process was conducted on line. Two 
reminders were sent at each round in case of non-response. 
This group responded using the Likert scale and the per-
centages were recorded. The experts assessed each proce-
dure using a score ranging from 1 to 9 based on increasing 
appropriateness. The question posed to experts was: How 
important do you consider the information obtainable 
from diagnostics for items on the area displayed in Table 2, 
in the evaluation of the patient with HIV infection?
Data on Delphi results
In the first Delphi round, each member of the panel evalu-
ated the clinical relevance of each of the diagnostic proce-
dures on a 9-point scale. For each procedure, the experts 
were asked to answer the following question: “Accord-
ing to you, how relevant is this procedure for a first-de-
gree assessment of comorbidities in HIV patients?”. A 
9-point scale with the anchors “not relevant at all” at 0 
and “extremely relevant” at 9 was used to record the re-
sponses. Experts were also invited to suggest additional 
procedures, not included in the questionnaire, which they 
nonetheless deemed appropriate for HIV patients in a first 
stage screening procedure. 
Table 1 - Criteria for bibliographic research.
Area Article From To
CV 88 2011 2015
DIA 21 2009 2015
OST 21 2011 2015
CKD 74 2011 2015
CNS 73 2011 2015
SNC 73 2011 2015
EPA 37 2011 2015
Table 2 - Items by clinical area.
Area ITEMs first-degree assessment 
ITEMs second-
degree assessment 
Medical History 42
Physical Examination 11
Infectious disease 
diagnosis 14 18
Osteoarticular 
diagnostics 7 12
Metabolic diagnostics 7 5
Cardiovascular 
diagnostics 8 12
Nephrology 
Diagnostics 13 18
Hepatic diagnosis 14 18
CNS diagnostics 11 17
Psycho Diagnostics 
and Quality of Life 3 4
Management of risk 
factor 14
Total 144 104
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They were added at the subsequent round provided the 
medical specialist in the respective field did not consider 
them redundant because of already existing similar pro-
cedures.
In the second round, the experts considered the same di-
agnostic procedure, and were also informed of each proce-
dure rating at the first round reporting. The experts were 
asked to rate each procedure again in light of the respons-
es at the first round. The concept of consensus within a 
group was defined as homogeneity or consistency of opin-
ion among the experts.
The criteria of agreement and disagreement among ex-
perts were defined as previously described (Brook, 1994; 
Fitch et al., 2001). In an attempt to anticipate the problem 
of how to deal with panels composed of more or fewer 
than nine members, the RAND/UCLA appropriateness 
method translated the definitions into a “somewhat sta-
tistical form”, framed as tests of hypotheses on the distri-
bution of ratings in a hypothetical population of repeated 
ratings by similarly selected panellists.
By this definition to define agreement we test the hypoth-
esis that 80% of the hypothetical population of repeated 
ratings are within the same  region (1-3, 4-6, 7-9) as the 
observed median. If we are unable to reject that hypoth-
esis on a binomial test at the 0.33 level, we say that the 
indication is rated “with agreement”.
Whereas to define disagreement we test the hypothesis 
that 90% of the hypothetical population of repeated rat-
ings are within one of two extra wide regions (1-6 or 4-9). 
If we have to reject that hypothesis on a binomial test at 
the 0.10 level, we conclude that the indication is rated 
“with disagreement”.
In conclusion we define:
1) Agreement -80% of panellists rating inside one of the 
3-point region (1-3, 4-6, 7-9);
2) disagreement -90% of panellists ratings are within one 
of two extra wide regions (1-6 or 4-9).
This level of consensus was decided a priori. Different con-
ditions of agreement and disagreement described above 
were rejected or modified. The collected assessments were 
evaluated for internal consistency and aggregated to ob-
tain a composite judgment.
The results of the poll were discussed by the Steering 
Committee, according to criteria of clinical appropriate-
ness and sustainability.
Statistical analysis
Calculations were performed using the Microsoft Office 
software package.
RESULTS
A total of 131 Items were divided into 10 first-level survey 
areas: anamnesis (42 items of which 21 in agreement), ob-
jective examination (12 items, 8 of which in agreement), 
infectious diseases (14 items, 9 of which in agreement), 
osteoporosis diagnosis (7 items, 5 of which in agreement), 
metabolic pathologies diagnosis (7 items, 6 of which in 
agreement) - cardiovascular diagnosis (8 items, 5 of which 
in agreement) nephrologic diagnosis (14 items, 9 of which 
in agreement), hepatological diagnosis (14 items, 13 of 
which in agreement), central nervous system diagnosis 
(11 items, 8 of which in agreement), evaluation of quality 
of life (QoL, 3 items, 1 of which in agreement) (Table 3).
DISCUSSION
There are many guidelines for the Use of Antiretroviral 
Agents in HIV-1-Infected Adults and Adolescents, but only 
a few analyze comorbidity management. In addition, rec-
ommendations are not similar and differences exist on 
several issues (Candel et al., 2017). This does not simpli-
fy the clinician’s work, because information is often dif-
ferent and sometimes recommendations are related to 
equipment not always available. Our study intentionally 
tested clinicians’ agreement on first-line investigations for 
comorbidity screening in a real life situation.
Concerning patient’s medical history, clinicians surpris-
ingly identified some heterogeneous ITEMs to be assessed, 
excluding in this phase other ones. They essentially con-
sidered a mix of personal, biological, laboratory, pharma-
cological, habit, clinical and sexual data as fundamental: 
age, sex, therapies in progress and previous, CD4 + nadir, 
CD4 progress - stable or in progressive improvement, risk 
factors for HIV, presence of symptoms, other past illnesses 
and pathologies in progress, drug consumption and type 
of drugs, alcohol consumption, smoking, food disorders 
(i.e. bulimia and anorexia or diet, vegetarian or vegan or 
hyper-protein consumption), pregnancies, menopause, 
condom use, partner serology (in the presence of a fixed 
partner), HIV-RNA zenith. In the clinicians’ shared opin-
ion, these data constitute the essential anamnesis to be 
carried out in each patient; other common data are con-
sidered less powerful in this first phase.Figure 1 - Delphi flow-chart.
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Table 3 - Results.
ITEMs to be assessed
Medical • Age
History • Sex
 • Therapies in progress
• Previous Therapy
• CD4 + nadir
• CD4 Progress - Stable
• CD4 Progress - In progressive 
Improvement
• Risk factors for HIV
• Presence of symptomatology
• Other past illness
• Pathologies in progress
• Drug consumption
• Type of drugs
• Alcohol consumption
• Smoke
• Food Disorders (eg bulimia and 
anorexia or diet, vegetarian or  
vegan or hyperprotein information)
• Pregnancies
• Menopause
• Condom use
• Partner serology (in the presence  
of a fixed partner)
• HIV-RNA zenith
General  ITEMs 
diagnostics to be assessed
Virological  • HIV-RNA
diagnostics • Genotypic resistance testing
Immunological  • Absolute CD4+ counts 
diagnostic • CD4%
 • CD4+/CD8+ Ratio
Screening for  • Syphilis 
co-infections • HBV
 • HAV
 • HCV
 • TBC
Osteoarticular ITEMs 
diagnostics to be assessed
Risk factors  • Medical history 
for osteoporosis
Estimate of risk • FRAX 
of osteoporosis  
fractures
Exclusion  • Level 1 Blood test: 
of other caused   ESR, 
of secondary   full blood count, 
osteoporosis  protein electrophoresis,
  serum calcium,
  phosphate,
  total alkaline phosphatase,
  creatinine,
  24 h urinary calcium
Diagnosis of  • 25 hydroxy Vitamin D 
osteomalacia • PTH
Metabolic   ITEMs 
diagnostics to be assessed
Risk factors for  • Medical history
dyslipidaemia 
Measurements • BMI
 • Waist circumference
Lipoartopy and  • PE 
lipohypertrophy 
Hyperglycaemia  • Lipid profile  
/diabetes,   (CT, TG, HDL, LDL) 
dyslipidaemia • Glycaemia
Cardiovascular   ITEMs 
diagnostics to be assessed
Risk factors • Family medical history
for CVD • Lipid profile 
  (CT, LDL, HDL, TG)
 • Glycaemia
 • AP
 • Waist circumference
CVD risk  • Framingham 
estimate 
Nephrology  ITEMs 
diagnostics to be assessed
Glomerular  • Calculation of the eGFR 
function  with CKD-EPI
Glomerular  • E.g. urine with sediment 
function/ 
nephrolithiasis
Loss of protein  • Ratio of protein/CR  
  in the urine
Exclusion of  • BP measurement 
other causes  • Medications 
of nephropathy   (including non-HIV)
Proximal tubule  • Phosphatemia 
function  • Phosphaturia
 • Glycaemia
 • Glycosuria
Hepatic    ITEMs 
diagnostics to be assessed
Liver cytolysis,  • ALT/AST ALP GGT 
cholestasis  • Bilirubin 
Exclude other  • History of viral infections 
causes of liver  • History of alcohol  
disease  consumption 
 • Presence of NASH
Exclude  • History of portal 
non-hepatic   hypertension 
causes of hyper  • Medication history 
ALT/AST • History of steatosis
Risk factors  • Medical history  
for liver disease 
Phisycal • Ascites 
examination  • Hepatic encephalopathy
Viral hepatitis • HBV serology 
serology • HCV serology
CNS    ITEMs 
diagnostics to be assessed
Exclusion  • History of depression 
of other  • History of anxiety 
neuropsychiatric   disorders 
disorders • History of other
  psychiatric disorders
 • Previous use of 
  psychoactive and 
  psychotropic substances
 • Current use psychoactive 
  and psychotropic  
  substances
 • Previous abuse of 
  psychotropic drugs
 • Alcoholism
Psyco ITEMs 
diagnostics and to be assessed
Quality of Live
Measurement  Adherence was investigated 
of adherence  with four separate questions, 
to therapy considering two different 
recall periods: last month and 
last week. For each period, 
patients were asked to report 
the proportion of doses taken 
and the proportion of doses 
taken with respect to the 
daily timing (±2 hours). In 
both cases a VAS scale was 
used collect data.
Metabolic pathologies diagnosis, 7 items, 6 of which in agreement - Cardiovascular diagnosis, 8 items, 5 of which in agreement - Nephrologic 
diagnosis, 14 items, 9 of which in agreement.
Hepatological diagnosis, 14 items, 13 of which in agreement – Central nervous system diagnosis, 11 items, 8 of which in agreement – Evaluation of 
Quality of Life (QoL), 3 items, 1 of which in agreement.
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Moving to general diagnostics, from the clinicians’ point 
of view only few ITEMs are really to be assessed during 
the first screening: two virologicaI (HIV-RNA plasma lev-
els and genotypic resistance testing), three immunological 
(absolute CD4+ counts, CD4%, and CD4+/CD8+ Ratio), and 
screening for co-infections (syphilis, HBV, HAV, HCV, TB).
Concerning osteoarticular diagnostics, clinicians iden-
tified specific ITEMs to be assessed. First of all, medical 
history, searching for risk factors for osteoporosis, in par-
ticular sex, age, race, family history, body frame size, sex 
hormones, thyroid problems, overactive parathyroid and 
adrenal glands, low calcium intake, eating disorders, gas-
trointestinal surgery, steroids and other medications used 
to combat or prevent seizures, gastric reflux, cancer, trans-
plant rejection, medical conditions (celiac disease, inflam-
matory bowel disease, kidney or liver disease, cancer, lu-
pus, multiple myeloma, rheumatoid arthritis), sedentary 
lifestyle, excessive alcohol consumption, and tobacco use. 
These are very important issues to decide for an activation 
toward second level investigations.
Very relevant is to estimate the risk of osteoporosis fractures 
with FRAX. This tool is based on individual patient models 
that integrate the risks associated with clinical risk factors 
as well as bone mineral density (BMD) at the femoral neck. 
The models have been developed from studying popula-
tion-based cohorts from Europe, North America, Asia and 
Australia. Is computer-driven and gives the 10-year proba-
bility of fracture. The output is a 10-year probability of hip 
fracture and the 10-year probability of a major osteoporotic 
fracture (clinical spine, forearm, hip or shoulder fracture).
Following SIOMMMS (Italian Society of Osteoporosis, 
Mineral Metabolism of bone diseases) guidelines, clini-
cians opted to include the ‘exclusion of other causes of 
secondary osteoporosis’ by implementation of erythrocyte 
sedimentation rate, full blood count, protein electrophore-
sis, serum calcium, phosphate, total alkaline phosphatase, 
creatinine, and 24 h urinary calcium. Diagnosis of osteo-
malacia, correctly done only by biopsy, is suggested by 25 
hydroxy-vitamin D and PTH plasma levels.
Interestingly, clinicians excluded DXA scan in this phase: 
indeed, DXA measures BMD, but osteoporosis is not a loss 
of bone mass, rather a loss of bone resistance, so we can 
observe fracture even with normal BMD values. In addi-
tion, DXA is not accessible to all clinicians.
Concerning metabolic diagnostics, clinicians analyzed 
ITEMs to be assessed in this phase. Even in this case, first 
they selected medical history, in order to evaluate the risk 
factors for dyslipidaemia, and in the perspective of a po-
tential second level of investigations.
Concerning measurements, only two calculations were se-
lected: body mass index (BMI) and Waist circumference. 
Waist circumference is mandatory, in order to consider 
visceral adipose tissue weight as the real estimate of cardi-
ovascular risks related to BMI. Physical examination was 
approved to define lipoatrophy and lipohypertrophy.
To evaluate hyperglycaemia/diabetes, and/or dyslipidae-
mia, lipid profile (CT, TG, HDL, LDL) and glycaemia are 
considered enough.
Concerning cardiovascular diagnostics, ITEMs to be as-
sessed partially overlap with metabolic ITEMs. First of all, 
clinicians shared medical history, searching for risk fac-
tors for cardiovascular disease (CVD), in particular family 
medical history, lipid profile (CT, LDL, HDL, TG), glycae-
mia, blood pressure determination, and waist circumfer-
ence measurement. For CVD risk estimate, Framingham’s 
algorithm was selected. The Framingham Risk Score is 
a gender-specific algorithm used to estimate the 10-year 
cardiovascular risk of an individual, developed starting 
from data obtained from the Framingham Heart Study, 
to estimate the 10-year risk of developing coronary heart 
disease. This tool has two limitations: it could predict only 
future coronary heart diseases, since it does not predict 
risk for stroke, transient ischemic attack (TIA), and heart 
failure, and could overestimate (or underestimate) risk in 
populations other than the US population.
Moving to nephrology diagnostics, from the clinicians’ 
point of view the following ITEMs should be assessed dur-
ing the first screening:
– the calculation of eGFR with CKD-EPI, in order to 
evaluate glomerular function;
– urine test with sediment to investigate glomerular 
function/nephrolithiasis;
– search for loss of protein, by means of the protein/cre-
atinine ratio in the urine.
As before, it is mandatory to exclude other causes of ne-
phropathy, through blood pressure measurement and a 
list of possible concomitant nephrotoxic medications (in-
cluding non-HIV drugs). In addition to glomerular func-
Table 4 - Assessment management.
Assessment management ITEMs to be assessed
Management of risk factors and 
comorbidities
It is advisable to monitor the risk of OSTEOPOROSIS in the patient  
with HIV six-monthly/annually (repeated first-level exams
It is advisable to monitor the risk of METABOLIC DISORDERS in the patient  
with HIV six-monthly/annually (repeat first-level texts)
It is advisable to monitor the risk of CARDIOVASCULAR disease the patient  
with HIV six-monthly/annually (repeat first-level texts)
It is advisable to monitor the risk of NEPHROPATY the patient  
with HIV six-monthly/annually (repeat first-leveltexts)
It is advisable to monitor the risk of LIVER DISEASE the patient  
with HIV six-monthly/annually (repeat first-level texts)
It is advisable to monitor the risk of NEUROLOGICAL disorders the patient  
with HIV six-monthly/annually (repeat first-level exams)
It is advisable to monitor the risk of PSYCHOLOGICAL CONDITION  
and QUALITY OF LIFE of the patient with HIV six-monthly/annually  
(repeat first-level exams)
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tion, proximal tubule function also needs to be investigat-
ed: clinicians also selected phosphataemia, phosphaturia, 
glycaemia and glycosuria.
Concerning hepatic diagnostics, ITEMs to be assessed 
in the clinicians’ opinion are essentially laboratory and 
clinical: first of all, medical history, searching for risk 
factors for liver disease. To investigate liver cytolysis and 
cholelithiasis, clinicians selected ALT, AST, ALP, GGT and 
bilirubin plasma levels. To exclude other causes of liver 
disease, they chose the history of viral infections and al-
cohol consumption, in addition to the presence of NASH, 
and physical examination, searching for the presence of 
ascites and/ hepatic encephalopathy to exclude non-hepat-
ic causes of hyper ALT/AST. Finally, regarding laboratory 
tests, clinicians selected HBV and HCV serology.
Moving to CNS Diagnostics, ITEMs to be assessed by cli-
nicians are those able to exclude other neuropsychiatric 
disorders: history of depression, history of anxiety disor-
ders, history of other psychiatric disorders, previous use 
of psychoactive and psychotropic substances, current 
use of psychoactive and psychotropic substances, current 
abuse of psychiatric drugs, previous abuse of psychotropic 
drugs, alcoholism.
Finally, concerning psychodiagnostics and Quality of Life 
ITEMs, the only one to be assessed in this first screening 
phase is the measurement of adherence to therapy, to be 
conducted as follows: adherence is investigated with four 
separate questions, considering two different recall peri-
ods: last month and last week. For each period, patients 
are asked to report the proportion of doses taken and the 
proportion of doses taken with respect to the daily timing 
(±2 hours). In both cases a VAS scale should be used to 
collect data.
To add advice concerning optimal timing of follow-up, cli-
nicians were asked for the assessment management of risk 
factors and comorbidities, regarding each specific ITEM 
(Table 4).
CONCLUSIONS
PLWHIV have changed, and it is time to find a new ap-
proach to better react to new challenges. Currently, few 
guidelines consider comorbidity issues, and sometimes 
with different diagnostic strategies. Our approach was 
based either on clinical practice or literature data. Our 
starting idea was that in order to find an agreement among 
clinicians is fundamental to a discuss and share a com-
mon approach to the same problems.
This simple and concise first-level tool identifies a few 
areas of multi-organ diagnostic assessment beyond the 
infectivity area, namely: osteoporosis, cardiovascular, 
metabolic, renal, hepatic, central nervous system and 
quality of life. The identification of these areas will al-
low us to find shared and validated evaluation proce-
dures with the intent to increase the likelihood of early 
recognition of patients at risk of comorbidity develop-
ment, in order to facilitate more effective prevention, 
thereby reducing the overall impact on the quality of life 
of patients affected by this chronic illness. Future steps 
will constitute specific technological support of a new 
practical tool for clinicians to effectively react to this 
fascinating new scenario.
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